Literature DB >> 24587677

Current issues in locally advanced colorectal cancer treated by preoperative chemoradiotherapy.

In Ja Park1, Chang Sik Yu1.   

Abstract

In patients with locally advanced rectal cancer, preoperative chemoradiotherapy has proven to significantly improve local control and cause lower treatment-related toxicity compared with postoperative adjuvant treatment. Preoperative chemoradiotherapy followed by total mesorectal excision or tumor specific mesorectal excision has evolved as the standard treatment for locally advanced rectal cancer. The paradigm shift from postoperative to preoperative therapy has raised a series of concerns however that have practical clinical implications. These include the method used to predict patients who will show good response, sphincter preservation, the application of conservative management such as local excision or "wait-and-watch" in patients obtaining a good response following preoperative chemoradiotherapy, and the role of adjuvant chemotherapy. This review addresses these current issues in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy.

Entities:  

Keywords:  Colorectal cancer; Conservative; Preoperative chemoradiotherapy; Rectal cancer; Response

Mesh:

Year:  2014        PMID: 24587677      PMCID: PMC3934472          DOI: 10.3748/wjg.v20.i8.2023

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  59 in total

1.  A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial.

Authors:  Julio Garcia-Aguilar; Qian Shi; Charles R Thomas; Emily Chan; Peter Cataldo; Jorge Marcet; David Medich; Alessio Pigazzi; Samuel Oommen; Mitchell C Posner
Journal:  Ann Surg Oncol       Date:  2011-07-14       Impact factor: 5.344

Review 2.  Can we increase the chance of sphincter saving surgery in rectal cancer with neoadjuvant treatments: lessons from a systematic review of recent randomized trials.

Authors:  Jean-Pierre Gerard; Yousri Rostom; Jocelyn Gal; Daniel Benchimol; Cécile Ortholan; Carlo Aschele; Jean-Michel Hannoun Levi
Journal:  Crit Rev Oncol Hematol       Date:  2011-03-05       Impact factor: 6.312

3.  Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings.

Authors:  Benjamin Movsas; J Donald Chapman; Alexandra L Hanlon; Eric M Horwitz; Richard E Greenberg; Corinne Stobbe; Gerald E Hanks; Alan Pollack
Journal:  Urology       Date:  2002-10       Impact factor: 2.649

4.  Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer.

Authors:  Jin-hong Park; Sang Min Yoon; Chang Sik Yu; Jong Hoon Kim; Tae Won Kim; Jin Cheon Kim
Journal:  Cancer       Date:  2011-02-15       Impact factor: 6.860

5.  Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution.

Authors:  Rodrigo Oliva Perez; Angelita Habr-Gama; Patricio Bernardo Lynn; Guilherme Pagin São Julião; Romina Bianchi; Igor Proscurshim; Joaquim Gama-Rodrigues
Journal:  Dis Colon Rectum       Date:  2013-01       Impact factor: 4.585

6.  Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.

Authors:  Angelita Habr-Gama; Rodrigo Oliva Perez; Wladimir Nadalin; Jorge Sabbaga; Ulysses Ribeiro; Afonso Henrique Silva e Sousa; Fábio Guilherme Campos; Desidério Roberto Kiss; Joaquim Gama-Rodrigues
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

7.  Oncologic outcome after preoperative chemoradiotherapy in patients with pathologic T0 (ypT0) rectal cancer.

Authors:  Tae Young Jang; Chang Sik Yu; Yong Sik Yoon; Seok-Byung Lim; Seung-Mo Hong; Tae Won Kim; Jong Hoon Kim; Jin Cheon Kim
Journal:  Dis Colon Rectum       Date:  2012-10       Impact factor: 4.585

8.  Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.

Authors:  In Ja Park; Y Nancy You; John M Skibber; Miguel A Rodriguez-Bigas; Barry Feig; Sa Nguyen; Chung-Yuan Hu; George J Chang
Journal:  Dis Colon Rectum       Date:  2013-02       Impact factor: 4.585

9.  Local excision after neoadjuvant chemoradiation therapy in advanced rectal cancer: a national multicenter analysis.

Authors:  Chang Sik Yu; Hae Ran Yun; Eung Jin Shin; Kang Yong Lee; Nam Kyu Kim; Seok-Byung Lim; Seong Taek Oh; Sung-Bum Kang; Won Joon Choi; Woo Yong Lee
Journal:  Am J Surg       Date:  2013-07-09       Impact factor: 2.565

10.  The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer.

Authors:  Christopher H Crane; John M Skibber; Elisa H Birnbaum; Barry W Feig; Anurag K Singh; Marc E Delclos; Edward H Lin; James W Fleshman; Howard D Thames; Ira J Kodner; Mary Ann Lockett; Joel Picus; Thinh Phan; Anshu Chandra; Nora A Janjan; Thomas E Read; Robert J Myerson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-09-01       Impact factor: 7.038

View more
  13 in total

Review 1.  Evolution of imaging in rectal cancer: multimodality imaging with MDCT, MRI, and PET.

Authors:  Siva P Raman; Yifei Chen; Elliot K Fishman
Journal:  J Gastrointest Oncol       Date:  2015-04

2.  T2-weighted signal intensity-selected volumetry for prediction of pathological complete response after preoperative chemoradiotherapy in locally advanced rectal cancer.

Authors:  Sungwon Kim; Kyunghwa Han; Nieun Seo; Hye Jin Kim; Myeong-Jin Kim; Woong Sub Koom; Joong Bae Ahn; Joon Seok Lim
Journal:  Eur Radiol       Date:  2018-06-01       Impact factor: 5.315

3.  The split scar sign as an indicator of sustained complete response after neoadjuvant therapy in rectal cancer.

Authors:  Inês Santiago; Maria Barata; Nuno Figueiredo; Oriol Parés; Vanessa Henriques; António Galzerano; Carlos Carvalho; Celso Matos; Richard J Heald
Journal:  Eur Radiol       Date:  2019-07-26       Impact factor: 5.315

4.  ELAS1-mediated inhibition of the cyclin G1-B'γ interaction promotes cancer cell apoptosis via stabilization and activation of p53.

Authors:  S Ohno; Y Naito; S Mukai; N Yabuta; H Nojima
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

5.  Multivisceral resections for rectal cancers: short-term oncological and clinical outcomes from a tertiary-care center in India.

Authors:  Vishwas D Pai; Sudhir Jatal; Vikas Ostwal; Reena Engineer; Supreeta Arya; Prachi Patil; Munita Bal; Avanish P Saklani
Journal:  J Gastrointest Oncol       Date:  2016-06

6.  MRI-defined high-risk rectal cancer patients: outcome comparison between neoadjuvant chemoradiotherapy plus TME and TME plus adjuvant chemotherapy or TME alone.

Authors:  Xiaoxuan Jia; Peiyi Xie; Liang Bi; Xiaochun Meng; Ziqiang Wang; Nan Hong; Yi Wang
Journal:  Br J Radiol       Date:  2021-02-16       Impact factor: 3.039

7.  Implications for selecting local excision in locally advanced rectal cancer after preoperative chemoradiation.

Authors:  Juefeng Wan; Kaitai Liu; Ji Zhu; Guichao Li; Zhen Zhang
Journal:  Oncotarget       Date:  2015-05-10

Review 8.  A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.

Authors:  Yi Li; Ji Wang; Xiaowei Ma; Li Tan; Yanli Yan; Chaofan Xue; Beina Hui; Rui Liu; Hailin Ma; Juan Ren
Journal:  Int J Biol Sci       Date:  2016-07-17       Impact factor: 6.580

9.  Sirtuin 7 promotes colorectal carcinoma proliferation and invasion through the inhibition of E-cadherin.

Authors:  Zhigang Deng; Xingbiao Wang; Xuan Long; Wanzhong Liu; Chunhua Xiang; Feng Bao; Dong Wang
Journal:  Exp Ther Med       Date:  2017-12-22       Impact factor: 2.447

10.  MRI Risk Stratification for Tumor Relapse in Rectal Cancer Achieving Pathological Complete Remission after Neoadjuvant Chemoradiation Therapy and Curative Resection.

Authors:  Honsoul Kim; Sungmin Myoung; Woong Sub Koom; Nam Kyu Kim; Myeong-Jin Kim; Joong Bae Ahn; Hyuk Hur; Joon Seok Lim
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.